Royal Bank of Canada
EWTX icon

Royal Bank of Canada’s Edgewise Therapeutics EWTX Stock Holding History

Royal Bank of Canada’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153K Sell
3,762
-2,111
-36% -$72.8K ﹤0.01% 5144
2026
Q1 		$185K Sell
5,873
-4,295
-42% -$124K ﹤0.01% 4757
2025
Q4 		$253K Sell
10,168
-5,527
-35% -$111K ﹤0.01% 4621
2025
Q3 		$254K Buy
15,695
+8,001
+104% +$113K ﹤0.01% 4933
2025
Q2 		$100K Buy
7,694
+1,965
+34% +$28.3K ﹤0.01% 5610
2025
Q1 		$126K Buy
5,729
+2,405
+72% +$63.1K ﹤0.01% 5056
2024
Q4 		$89K Sell
3,324
-5,590
-63% -$178K ﹤0.01% 5399
2024
Q3 		$238K Buy
8,914
+1,341
+18% +$26.7K ﹤0.01% 4674
2024
Q2 		$136K Buy
7,573
+5,581
+280% +$97.3K ﹤0.01% 5061
2024
Q1 		$37K Sell
1,992
-12,092
-86% -$192K ﹤0.01% 5658
2023
Q4 		$154K Buy
14,084
+6,182
+78% +$43.4K ﹤0.01% 5308
2023
Q3 		$45K Buy
7,902
+2,738
+53% +$18.6K ﹤0.01% 5837
2023
Q2 		$40K Buy
5,164
+2,339
+83% +$19.7K ﹤0.01% 5879
2023
Q1 		$19K Sell
2,825
-1,547
-35% -$14.3K ﹤0.01% 6044
2022
Q4 		$39K Buy
4,372
+3,160
+261% +$29.6K ﹤0.01% 6024
2022
Q3 		$12K Buy
1,212
+194
+19% +$1.96K ﹤0.01% 6343
2022
Q2 		$8K Sell
1,018
-2,209
-68% -$16.7K ﹤0.01% 6460
2022
Q1 		$31K Sell
3,227
-12,425
-79% -$160K ﹤0.01% 6362
2021
Q4 		$239K Buy
15,652
+14,251
+1,017% +$256K ﹤0.01% 5158
2021
Q3 		$24K Buy
1,401
+557
+66% +$10.1K ﹤0.01% 6606
2021
Q2 		$18K Buy
+844
New +$23.1K ﹤0.01% 6616

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Royal Bank of Canada's EWTX Position: Q2 2026 in Review

Royal Bank of Canada reduced its Edgewise Therapeutics (EWTX) stake by 36% in Q2 2026, selling an estimated $72.8K and leaving 3,762 shares worth $153K. The position accounts for ﹤0.01% of the portfolio, ranked #5144.

Royal Bank of Canada first reported a position in EWTX in Q2 2021 and has held it in 21 quarters since. The position peaked at $254K in Q3 2025. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Royal Bank of Canada held 3,762 shares of Edgewise Therapeutics worth $153K as of Q2 2026.
  • Royal Bank of Canada sold 2,111 Edgewise Therapeutics shares in Q2 2026, an estimated $72.8K.
  • Edgewise Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #5144 holding.
  • Royal Bank of Canada first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Royal Bank of Canada's Edgewise Therapeutics position peaked at $254K in Q3 2025.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.